APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Syncytial Virus Vaccine for the Elderly

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Respiratory Syncytial Virus Vaccine for the Elderly Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchRespiratory Syncytial Virus Vaccine for the Elderly Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Syncytial Virus Vaccine for the Elderly Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Respiratory Syncytial Virus Vaccine for the Elderly market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Respiratory Syncytial Virus Vaccine for the Elderly is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Syncytial Virus Vaccine for the Elderly market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Syncytial Virus Vaccine for the Elderly and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Syncytial Virus Vaccine for the Elderly sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Syncytial Virus Vaccine for the Elderly market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Company

GSK

Icosavax

Moderna

Pfizer

RNAimmune

Sanofi

Advaccine

Daiichi Sankyo

Immorna

Blue Lake Biotechnology

Clover Biopharma

Innorna

Starna Therapeutics

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type

Recombinant Protein Vaccine

Nucleic Acid Vaccines

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Syncytial Virus Vaccine for the Elderly market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Respiratory Syncytial Virus Vaccine for the Elderly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends Table 2. Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers Table 3. Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges Table 4. Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers (Units) & (2021-2026) Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Manufacturers Table 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers, Product Type & Application Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Recombinant Protein Vaccine Table 17. Major Manufacturers of Nucleic Acid Vaccines Table 18. Major Manufacturers of Others Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026) Table 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2027-2032) Table 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type 2021 VS 2025 VS 2032 (Units) Table 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (Units) Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (Units) Table 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026) Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Centers for Disease Control and Prevention Table 31. Major Manufacturers of Others Table 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application 2021 VS 2025 VS 2032 (Units) Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 34. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 35. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026) Table 36. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2027-2032) Table 37. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application 2021 VS 2025 VS 2032 (Units) Table 38. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (Units) Table 39. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (Units) Table 40. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2026) Table 41. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2027-2032) Table 42. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 43. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Units) Table 44. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2026) Table 45. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecasted by Region (2027-2032) & (Units) Table 46. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 48. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 49. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 50. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 51. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 52. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 53. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 54. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 55. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 56. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 57. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 58. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 59. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2026) Table 63. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2027-2032) Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 68. GSK Recent Development Table 69. Icosavax Company Information Table 70. Icosavax Business Overview Table 71. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 73. Icosavax Recent Development Table 74. Moderna Company Information Table 75. Moderna Business Overview Table 76. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 78. Moderna Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 83. Pfizer Recent Development Table 84. RNAimmune Company Information Table 85. RNAimmune Business Overview Table 86. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 88. RNAimmune Recent Development Table 89. Sanofi Company Information Table 90. Sanofi Business Overview Table 91. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 93. Sanofi Recent Development Table 94. Advaccine Company Information Table 95. Advaccine Business Overview Table 96. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 98. Advaccine Recent Development Table 99. Daiichi Sankyo Company Information Table 100. Daiichi Sankyo Business Overview Table 101. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 103. Daiichi Sankyo Recent Development Table 104. Immorna Company Information Table 105. Immorna Business Overview Table 106. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 108. Immorna Recent Development Table 109. Blue Lake Biotechnology Company Information Table 110. Blue Lake Biotechnology Business Overview Table 111. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 113. Blue Lake Biotechnology Recent Development Table 114. Clover Biopharma Company Information Table 115. Clover Biopharma Business Overview Table 116. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 118. Clover Biopharma Recent Development Table 119. Innorna Company Information Table 120. Innorna Business Overview Table 121. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 123. Innorna Recent Development Table 124. Starna Therapeutics Company Information Table 125. Starna Therapeutics Business Overview Table 126. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 128. Starna Therapeutics Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List Table 132. Respiratory Syncytial Virus Vaccine for the Elderly Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Respiratory Syncytial Virus Vaccine for the Elderly Product Image Figure 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (2021-2032) & (US$ Million) Figure 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2021-2032) & (Units) Figure 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Respiratory Syncytial Virus Vaccine for the Elderly Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Recombinant Protein Vaccine Image Figure 9. Nucleic Acid Vaccines Image Figure 10. Others Image Figure 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2032) Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021 VS 2025 VS 2032) & (Units) Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Centers for Disease Control and Prevention Image Figure 19. Others Image Figure 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2032) Figure 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021 VS 2025 VS 2032) & (Units) Figure 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2032) Figure 26. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 27. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 28. U.S. Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 29. Canada Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 30. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 31. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 32. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 33. Germany Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 34. France Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 35. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 36. Italy Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 37. Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 38. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 39. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 40. China Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 41. Japan Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 42. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 43. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 44. India Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 45. Australia Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 46. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 47. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2032) Figure 48. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 49. South Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 50. Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 51. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 52. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 53. UAE Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 54. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 55. Chile Respiratory Syncytial Virus Vaccine for the Elderly Sales and Growth Rate (2021-2032) & (Units) Figure 56. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Figure 59. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Figure 61. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Nucleic Acid Vaccines
  • Others
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • GSK
  • Icosavax
  • Moderna
  • Pfizer
  • RNAimmune
  • Sanofi
  • Advaccine
  • Daiichi Sankyo
  • Immorna
  • Blue Lake Biotechnology
  • Clover Biopharma
  • Innorna
  • Starna Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
  1. 2.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
  2. 2.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
  3. 2.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
  4. 2.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
3 Respiratory Syncytial Virus Vaccine for the Elderly Market by Manufacturers
  1. 3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers (2021-2026)
  3. 3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers, Product Type & Application
  7. 3.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Respiratory Syncytial Virus Vaccine for the Elderly Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Respiratory Syncytial Virus Vaccine for the Elderly Tier 1, Tier 2, and Tier 3
4 Respiratory Syncytial Virus Vaccine for the Elderly Market by Type
  1. 4.1 Respiratory Syncytial Virus Vaccine for the Elderly Type Introduction
  2. 4.1.1 Recombinant Protein Vaccine
  3. 4.1.2 Nucleic Acid Vaccines
  4. 4.1.3 Others
  5. 4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type
  6. 4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032)
  8. 4.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2032)
  9. 4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type
  10. 4.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032)
  12. 4.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2032)
5 Respiratory Syncytial Virus Vaccine for the Elderly Market by Application
  1. 5.1 Respiratory Syncytial Virus Vaccine for the Elderly Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application
  6. 5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032)
  8. 5.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2032)
  9. 5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application
  10. 5.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032)
  12. 5.3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2032)
6 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region
  1. 6.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026)
  4. 6.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region
  1. 7.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region
  2. 7.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026)
  4. 7.1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2027-2032)
  5. 7.1.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032)
  8. 7.2.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032)
  11. 7.3.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Icosavax
  8. 8.2.1 Icosavax Company Information
  9. 8.2.2 Icosavax Business Overview
  10. 8.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  12. 8.2.5 Icosavax Recent Developments
  13. 8.3 Moderna
  14. 8.3.1 Moderna Company Information
  15. 8.3.2 Moderna Business Overview
  16. 8.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  18. 8.3.5 Moderna Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 RNAimmune
  26. 8.5.1 RNAimmune Company Information
  27. 8.5.2 RNAimmune Business Overview
  28. 8.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  30. 8.5.5 RNAimmune Recent Developments
  31. 8.6 Sanofi
  32. 8.6.1 Sanofi Company Information
  33. 8.6.2 Sanofi Business Overview
  34. 8.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  36. 8.6.5 Sanofi Recent Developments
  37. 8.7 Advaccine
  38. 8.7.1 Advaccine Company Information
  39. 8.7.2 Advaccine Business Overview
  40. 8.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  42. 8.7.5 Advaccine Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 Immorna
  50. 8.9.1 Immorna Company Information
  51. 8.9.2 Immorna Business Overview
  52. 8.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  54. 8.9.5 Immorna Recent Developments
  55. 8.10 Blue Lake Biotechnology
  56. 8.10.1 Blue Lake Biotechnology Company Information
  57. 8.10.2 Blue Lake Biotechnology Business Overview
  58. 8.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  60. 8.10.5 Blue Lake Biotechnology Recent Developments
  61. 8.11 Clover Biopharma
  62. 8.11.1 Clover Biopharma Company Information
  63. 8.11.2 Clover Biopharma Business Overview
  64. 8.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  66. 8.11.5 Clover Biopharma Recent Developments
  67. 8.12 Innorna
  68. 8.12.1 Innorna Company Information
  69. 8.12.2 Innorna Business Overview
  70. 8.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  72. 8.12.5 Innorna Recent Developments
  73. 8.13 Starna Therapeutics
  74. 8.13.1 Starna Therapeutics Company Information
  75. 8.13.2 Starna Therapeutics Business Overview
  76. 8.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  78. 8.13.5 Starna Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
  2. 9.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process
  6. 9.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
  9. 9.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst